Yukio Nagasaki (Japan)

University of Tsukuba Materials Science
Yukio Nagasaki was born in 1959. He received B.S. and Ph.D. degrees in Engineering School of Science University of Tokyo in 1982, and 1987. Since 1987, he was working Science University of Tokyo as Research Associate, Assistant Professor, Associate Professor and Professor. In 2004, he moved to Graduate School of Pure and Applied Sciences, University of Tsukuba. He published more than 200 scientific papers. He received several awards such as The Award of Japanese Society for Biomaterials (2014), The Nagai Award from The Japan Society of Drug Delivery System (2015) and Polymer Society award, Japan (2017). Recent his research area is the development of novel self-assembling drugs.

Author Of 1 Presentation

 Conference Calendar
Free Communication

DESIGN OF POLY(DOPA)-BASED NANOPARTICLE FOR PARKINSON’S DISEASE TREATMENT WITH SUPPRESSING DYSKINESIA

Session Type
Free Communication
Session Name
1790 - FREE COMMUNICATION: Other (ID 222)
Date
07.10.2021, Thursday
Session Time
11:30 - 13:00
Room
Free Communication C
Lecture Time
12:10 - 12:20
Presenter
  • Yukio Nagasaki (Japan)

Abstract

Background and Aims:

fig1.jpgThe major cause of Parkinson's disease (PD) is thought to be the loss of dopaminergic substantia nigra neurons and the formation of alpha-synuclein-containing Lewy bodies. Although dopamine supplementation is a vital therapy, it is not facile to cross the BBB. 3,4-Dihydroxyphenylalanine (L-DOPA), a dopamine precursor, is one of the main drugs to treat PD since L-DOPA can cross the BBB better than dopamine; however, there are strong demands to develop further effective drugs due to the short half-life and several adverse effects such as dyskinesia. In this study, we studied new drugs based on novel molecular self-assembling at overcoming the drawbacks of L-DOPA and creating safe and effective Parkinson's disease drugs, viz., a nanoparticle consists of poly(diacetyl L-DOPA) was designed, which improved the controlled release of L-DOPA and improved the therapeutic effects, suppressing its adverse effects.

Methods:

A newly designed hydrophilic-hydrophobic block copolymer poly(ethylene glycol)-b-poly (L-DOPA(diacetyl)) forms self-assembling nano-sized particle (NanoDOPA), which is examined to the effect on Parkinson's disease model mice.

Results:

fig2.jpgfig3.jpgNanoDOPA significantly prolonged the retention of L-DOPA in the blood (mouse; n=3) and not only showed recovery in Parkinson's disease mice (n=8) but also reduced Dyskinesia symptoms (n=8).

Conclusions:

NanoDOPA is anticipated as a new high-performance Parkinson's disease drug.

Hide

Presenter of 1 Presentation

 Conference Calendar
Free Communication

DESIGN OF POLY(DOPA)-BASED NANOPARTICLE FOR PARKINSON’S DISEASE TREATMENT WITH SUPPRESSING DYSKINESIA

Session Type
Free Communication
Session Name
1790 - FREE COMMUNICATION: Other (ID 222)
Date
07.10.2021, Thursday
Session Time
11:30 - 13:00
Room
Free Communication C
Lecture Time
12:10 - 12:20
Presenter
  • Yukio Nagasaki (Japan)

Abstract

Background and Aims:

fig1.jpgThe major cause of Parkinson's disease (PD) is thought to be the loss of dopaminergic substantia nigra neurons and the formation of alpha-synuclein-containing Lewy bodies. Although dopamine supplementation is a vital therapy, it is not facile to cross the BBB. 3,4-Dihydroxyphenylalanine (L-DOPA), a dopamine precursor, is one of the main drugs to treat PD since L-DOPA can cross the BBB better than dopamine; however, there are strong demands to develop further effective drugs due to the short half-life and several adverse effects such as dyskinesia. In this study, we studied new drugs based on novel molecular self-assembling at overcoming the drawbacks of L-DOPA and creating safe and effective Parkinson's disease drugs, viz., a nanoparticle consists of poly(diacetyl L-DOPA) was designed, which improved the controlled release of L-DOPA and improved the therapeutic effects, suppressing its adverse effects.

Methods:

A newly designed hydrophilic-hydrophobic block copolymer poly(ethylene glycol)-b-poly (L-DOPA(diacetyl)) forms self-assembling nano-sized particle (NanoDOPA), which is examined to the effect on Parkinson's disease model mice.

Results:

fig2.jpgfig3.jpgNanoDOPA significantly prolonged the retention of L-DOPA in the blood (mouse; n=3) and not only showed recovery in Parkinson's disease mice (n=8) but also reduced Dyskinesia symptoms (n=8).

Conclusions:

NanoDOPA is anticipated as a new high-performance Parkinson's disease drug.

Hide